Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Trial details
- Registry ID
- NCT03070392
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaNCT03070392 | Immunocore Ltd | Phase 2 | Completed | 2020-10-13Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |